A Study of the Efficacy and Safety of the LEISH-F2 + MPL-SE Vaccine for Treatment of Cutaneous Leishmaniasis
NCT01011309
·
clinicaltrials.gov ↗
PHASE2
Phase
COMPLETED
Status
45
Enrollment
OTHER
Sponsor class
Conditions
Cutaneous Leishmaniasis
Interventions
BIOLOGICAL:
LEISH-F2 + MPL-SE
DRUG:
Sodium stibogluconate
Sponsor
Access to Advanced Health Institute (AAHI)